The oral PCSK9 inhibitor enlicitide can change cholesterol management with high efficacy and improved adherence, said Ann Marie Navar, MD, PhD.
Ann Marie Navar, MD, PhD
Advertisement
Ann Marie Navar, MD, PhD, is an associate professor in the departments of internal medicine and population and data sciences at UT Southwestern Medical Center.
Articles by Ann Marie Navar, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Improving Patient-Centered Cardiovascular Care for Older Adults
3
Introduction of Work Requirements to Medicaid Enrollment Could Destabilize Health: William Schpero, PhD, MPhil, MPH
4
Gefurulimab for MG Exhibits Lasting Efficacy, Safety in Topline PREVAIL Trial Data
5
